Dr. Ellen Donnelly joined Juvenescence in the spring of 2020 as the CEO of the Epigenetics Division and CEO of its portfolio company, Souvien Bio Ltd, a biotechnology company focused on developing novel therapeutic agents to modulate critical epigenetic mechanisms associated with neurodegeneration. 

Ellen was previously the CEO of Modus Therapeutics AB, based in Stockholm, Sweden, focused on developing therapies to improve blood flow and oxygen transport.  While at Modus, Ellen moved the lead candidate, sevuparin, through global development in sickle cell disease. 

Ellen brings a strong background in neuroscience to the company from her prior leadership positions at Pfizer across research and development, from clinical operations to research, project management and strategy.  Prior to joining Pfizer, Ellen was a Therapeutic Area Lead at CombinatoRx, Inc. where she led a Phase 2 program in Rheumatoid Arthritis and was responsible for the Neuroscience portfolio.  

Ellen has a PhD in Pharmacology and Neuroscience from Yale University where she studied the modulation of voltage-gated sodium channels in disease.  After receiving her PhD, Ellen worked in management consulting with MEDACorp/Leerink Swann Strategic Advisors, a consulting group within the healthcare investment bank now called SVB Leerink.